GT Medical Technologies Announces 2022 GammaTile® ELITE Brain Tumor Centers
Friday, March 10, 2023
GT Medical Technologies, Inc. announced its latest roster of ELITE Brain Tumor Centers that have received the distinction for completing 10 or more GammaTile Therapy procedures in 2022.
This year's ELITE inductees are AdventHealth Neuroscience Institute (Florida), Brooke Army Medical Center (Texas), North Carolina Basnight Cancer Hospital (North Carolina), Tampa General Hospital (Florida), UT Health San Antonio (Texas), UT Southwestern Medical Center (Texas), and Westchester Medical Center (New York).
These hospitals join the existing ELITE brain tumor specialists from 2020-2021, including ECU Health Medical Center (North Carolina), Emory Healthcare (Georgia), HonorHealth Scottsdale Osborn Medical Center (Arizona), M Health Fairview (Minnesota), Mayfield Brain & Spine (Ohio), Memorial Sloan Kettering Cancer Center (New York), NorthShore University Health System (Illinois), Piedmont Atlanta Hospital (Georgia), and The University of Kansas Health System (Kansas).
GammaTile ELITE institutions share GT Medical Technologies' purpose of improving the lives of patients with brain tumors. These distinguished medical centers are each committed to excellence by putting the quality of life for their patients first and embracing evidence-based innovation.
"GammaTile allows patients to have their brain tumors treated in one fell swoop. Given that the radiation sources are implanted at the time of surgery, patients are spared the hassle of returning to the hospital for traditional radiation," said Simon Hanft, MD, Chief of Neurosurgical Oncology at Westchester Medical Center. "It gets their treatment started immediately. No more waiting for life-prolonging treatment--it all begins now."
GammaTile Therapy features a bioresorbable, conformable, 3D-collagen tile embedded with radiation sources. It is implanted in the last five minutes of brain tumor removal surgery. The sustained, controlled, and therapeutic dose of radiation immediately begins targeting tumor cells, sparing healthy tissue. Patients receive their radiation treatment while going about their daily life, without the necessity of daily trips to a medical center for external radiation. Over time, the tile naturally resorbs into the adjacent tissue with no need for additional surgery to remove it. GammaTile Therapy is shown to improve local tumor control, which can extend a patient's life.
"GammaTile is a game changer for those with recurrent or newly occurring brain tumors, as it offers innovative options not previously available to patients," stated John David, MD, Assistant Professor in the Department of Radiology in the USF Health Morsani College of Medicine, Tampa, Fla. and Radiation Oncologist and Director of Brachytherapy Services at Tampa General Hospital. "Because it emits internal radiation in the specific area of the tumor, GammaTile has the ability to prevent the growth of residual cancer cells."
GammaTile was FDA-cleared in 2018 for recurrent malignant brain tumors, including recurrent high-grade gliomas, glioblastomas, meningiomas, and brain metastases. In 2020, the FDA expanded that indication to include newly diagnosed malignant brain tumors. Since becoming available, hundreds of patients across the United States have received the Therapy. A map of GammaTile centers is available at GammaTile.com.
"There are over 80 hospitals offering GammaTile to their patients with brain tumors and 20 of those hospitals are designated ELITE," said Matt Likens, president, and CEO of GT Medical Technologies. "We commend these ELITE centers for offering advanced technologies like GammaTile that are helping patients live longer while improving their quality of life."